original ) (raw )Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients
A. Kusic-pajic
International Journal of Cardiology, 2014
View PDFchevron_right
Survival with first-line bosentan in patients with primary pulmonary hypertension
O. Sitbon
European Respiratory Journal, 2005
View PDFchevron_right
[Long-term outcomes of treatment with bosentan in pulmonary hypertension]
Carlos Jhair Perez Bravo
Archivos de bronconeumología, 2006
View PDFchevron_right
Bosentan therapy for pulmonary arterial hypertension
Gerald Simonneau
Future Cardiology, 2005
View PDFchevron_right
Quality of Life in Pulmonary Arterial Hypertension: Improvement and Maintenance With Bosentan
Trevor Williams
The Journal of Heart and Lung Transplantation, 2007
View PDFchevron_right
hypertension echocardiographicand doppler measures in patients with pulmonary arterial Effects of the oral endothelin-receptorantagonist bosentan on
Tomas Pulido
2000
View PDFchevron_right
Bosentan for patients with chronic thromboembolic pulmonary hypertension
Marco Confalonieri , A. Potena
European Journal of Internal Medicine, 2009
View PDFchevron_right
Review of bosentan in the management of pulmonary arterial hypertension
Eli Gabbay
Vascular health and risk management, 2007
View PDFchevron_right
Efficacy of bosentan in the treatment of pulmonary hypertension; a prospective study focusing on safety and efficacy in patients with COPD
Neeta Maheshwary
Journal of Lung, Pulmonary & Respiratory Research
View PDFchevron_right
Bosentan for the Treatment of Pulmonary Arterial Hypertension
Peter Macdonald
The Annals of Pharmacotherapy, 2003
View PDFchevron_right
Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension
Namsik Chung
Korean circulation journal, 2009
View PDFchevron_right
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Jay Jay
European Respiratory Journal, 2006
View PDFchevron_right
Effects of the oral endothelin receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension
Nilda Espinola-Zavaleta
Journal of the American College of Cardiology, 2002
View PDFchevron_right
Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension
Zhuoli Zhang
The Journal of Heart and Lung Transplantation, 2010
View PDFchevron_right
Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect
Michele D'Alto
Heart, 2007
View PDFchevron_right
Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease
Mehmet Kaya
Heart, 2007
View PDFchevron_right
Effect of Bosentan on Pulmonary Hypertension Secondary to Systolic Heart Failure
Sonia Bernazzali
Pharmacology, 2013
View PDFchevron_right
Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan
Alfred Nona , Carlo Iacoboni , Serena Marcon
International Journal of Cardiology, 2013
View PDFchevron_right
Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study
Sotiria Apostolopoulou
Heart, 2007
View PDFchevron_right
Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era
Monika Brand
The Journal of Heart and Lung Transplantation, 2010
View PDFchevron_right
Effects of Bosentan on Peripheral Endothelial Function in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
Akihiro Hirashiki
Pulmonary Circulation, 2016
View PDFchevron_right